Foresee Pharmaceuticals begins FP-025 phase 2/3 trial in Covid-19 associated ARDS

Foresee Pharmaceuticals has started patient dosing in a phase 2/3 trial of FP-025 in adults having severe to critical Covid-19 with associated acute respiratory distress ... Read More